Lifitegrast
- Generic Name
- Lifitegrast
- Brand Names
- Xiidra
- Drug Type
- Small Molecule
- Chemical Formula
- C29H24Cl2N2O7S
- CAS Number
- 1025967-78-5
- Unique Ingredient Identifier
- 038E5L962W
- Background
Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting .
- Indication
适用于治疗干眼病（DED）的症状和体征。
- Associated Conditions
- Dry Eye Syndrome (DES)
A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 711
- Registration Number
- NCT02284516
- Locations
- 🇺🇸
Chicago Cornea Consultants, Ltd., Hoffman Estates, Illinois, United States
🇺🇸Jackson Eye, SC, Lake Villa, Illinois, United States
🇺🇸Lifelong Vision Foundation, Chesterfield, Missouri, United States
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Shire
- Target Recruit Count
- 720
- Registration Number
- NCT01743729
- Locations
- 🇺🇸
OPUS-2 Investigational Site, Norfolk, Virginia, United States
🇺🇸OPUS-2 Investigational SIte, Rancho Cordova, California, United States
Safety Study of Lifitegrast to Treat Dry Eye
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 332
- Registration Number
- NCT01636206
- Locations
- 🇺🇸
SONATA Investigational Site, Houston, Texas, United States
Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
- Conditions
- Keratoconjunctivitis SiccaDry Eye Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-08-22
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 588
- Registration Number
- NCT01421498
- Locations
- 🇺🇸
OPUS-1 Investigational Site, Norfolk, Virginia, United States
A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
- First Posted Date
- 2009-06-23
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 230
- Registration Number
- NCT00926185
- Locations
- 🇺🇸
Mundorf Eye Center, Charlotte, North Carolina, United States
🇺🇸The Eye Care Group, Waterbury, Connecticut, United States
🇺🇸Central Maine Eye Care, Lewiston, Maine, United States
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Shire
- Target Recruit Count
- 60
- Registration Number
- NCT00882687
- Locations
- 🇺🇸
Ora, Andover, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.